Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U4 small nuclear 13, pseudogene (RNU4-13P) is a human gene classified as a pseudogene of the U4 small nuclear RNA (snRNA) family[1][6]. Unlike functional snRNAs, which are core components of the spliceosome complex essential for pre-mRNA splicing, pseudogenes like RNU4-13P are typically non-functional remnants arising from gene duplication or retrotransposition events and generally do not encode active RNA molecules or proteins[1][6]. There is no evidence implicating RNU4-13P in cellular function, disease, or therapeutic modulation; it does not appear in drug target databases and has no reported interacting drugs, biomarkers, or safety concerns[1][6]. Clarification: Recent neurodevelopmental disorder (NDD) research centers on a different small nuclear RNA gene, RNU4-2, which encodes the functional U4 snRNA subunit of the spliceosome and is implicated in disease when mutated[4][5][7][8][9]. However, these findings do not apply to RNU4-13P, which remains a non-functional pseudogene without any known role in splicing, disease, or therapy.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 13, pseudogene (RNU4-13P).